Research in a nutshell

It is scientific excellence that leads to the healthcare breakthroughs of tomorrow. At Roche, we are tireless in the research and development of clinically differentiated pharmaceuticals and adequate diagnostic instruments for five disease areas:

  • Oncology
  • Metabolism
  • Virology
  • Inflammation
  • Central nervous system

As a company active in both diagnostics and pharmaceuticals, we are pioneering the area of personalised healthcareat the interface between the two fields. Our first personalised products tailored to the needs of specific patient groups are already being marketed. One example is the AmpliChip, a test that allows individualised dosing based on metabolic profiling. It was the first pharmacogenetic test to be officially recognised by the FDA.
In everything we do, we actively explore new avenues for instance, in biotechnology. It is our deep belief that the future of innovation will depend greatly on the advances made there from therapeutic proteins to new developments in siRNA technologies, biomarkers, translational medicine, and bioinformatics. Innovations like these have enabled us to successfully pursue new therapeutic approaches, particularly in oncology. Over the past years we have been focusing on the following technological platforms:

  • Synthesis and Screening (Ultra-High Throughput Screening)
  • Combinatorial Chemistry
  • 3D Modelling
  • Genetics, Genomics
  • Pharmacogenetics
  • Proteomics
  • Bioinformatics

Roche research sites are located around the world, including Switzerland, the United States, Germany, and Shanghai, China. In addition, we have co-development partnerships with Genentech (USA) and Chugai (Japan).

Our research teams have won a number of awards, including:

Nobel Prize in Physiology or Medicine:

  • 1987 Awarded to Susumu Tonegawa, Basel Institute for Immunology (BII), for his work on the genetic origins of antibody diversity
  • 1984 Awarded to Niels Kaj Jerne, together with Georges Khler, Basel Institute for Immunology (BII), and Csar Milstein, MRC Laboratory of Molecular Biology, Cambridge, United Kingdom for the discovery of monoclonal antibodies

Prix Galien prizes:

  • 2004 International Prix Galien for Fuzeon
  • 1998 European Prix Galien for Invirase
  • 1998 Prix Galien for Anexate
  • 1992 International Prix Galien for Neupogen

You could help us win the next one!

So, regardless of whether your degree is in biology, biochemistry, biotechnology, chemistry, pharmacy or engineering at Roche, you will have the opportunity to apply your experience, assume responsibility, and join us in shaping the future.

Tags: Research & Development